SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $642,575,985 |
| Positions | 23 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| CG Oncology, Inc. | CGON | COM | $168,358,233 | 2,369,574 |
| ALUMIS INC. | ALMS | COM | $119,529,434 | 4,247,670 |
| Seaport Therapeutics, Inc. | SPTX | COM | $38,651,196 | 1,779,521 |
| Denali Therapeutics Inc. | DNLI | COM | $35,924,950 | 1,396,771 |
| Celldex Therapeutics, Inc. | CLDX | COM | $32,734,121 | 879,713 |
| AGIOS PHARMACEUTICALS, INC. | AGIO | COM | $29,131,350 | 785,000 |
| Corvus Pharmaceuticals, Inc. | CRVS | COM | $27,358,621 | 1,831,233 |
| Parabilis Medicines, Inc. | PBLS | COM | $27,343,834 | 999,044 |
| GH Research PLC | GHRS | ORD | $25,280,452 | 940,493 |
| Jade Biosciences, Inc. | JBIO | COM | $19,701,741 | 886,667 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.